Emphysema Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Emphysema pipeline constitutes 10+ key companies continuously working towards developing 12+ Emphysema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Emphysema Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Emphysema Market.

The Emphysema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Emphysema Pipeline Report: https://www.delveinsight.com/sample-request/emphysema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Emphysema treatment therapies with a considerable amount of success over the years.
• Emphysema companies working in the treatment market are Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi, Mesoblast, Inc., and others, are developing therapies for the Emphysema treatment
• Emerging Emphysema therapies in the different phases of clinical trials are- Kamada AAT for inhalation, RAR Gamma, BLVR System, Alpha-1 MP, SAR447537, ProchymalTM, and others are expected to have a significant impact on the Emphysema market in the coming years.
• In May 2025, Apreo Health, a clinical-stage medical device company focused on developing an innovative, tissue-preserving treatment for severe emphysema, announced the presentation of six-month, first-in-human clinical data from its BREATHE 1&2 trials. The data were featured in a late-breaking abstract session at the American Thoracic Society (ATS) 2025 International Conference in San Francisco and concurrently published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).
• The BREATHE trials mark the first clinical assessment of Apreo's BREATHE Airway Scaffold, a bronchoscopically delivered, self-expanding implant designed to reduce lung hyperinflation in emphysema patients by enabling the release of trapped air.
• In January 2025, Aer Therapeutics (Aer), a biopharmaceutical company dedicated to advancing inhaled treatments for mucus-related lung conditions, announced the dosing of the first patient in its Phase 2a proof-of-concept (POC) clinical trial of fexlamose (formerly AER-01) for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Emphysema Overview
Emphysema is a chronic lung condition that is part of Chronic Obstructive Pulmonary Disease (COPD). It occurs when the air sacs (alveoli) in the lungs become damaged and lose their elasticity, making it difficult to breathe out fully. This leads to shortness of breath, especially during physical activity. The primary cause is long-term exposure to cigarette smoke, though air pollution and occupational fumes can also contribute. Emphysema is progressive and has no cure, but treatments like inhalers, medications, pulmonary rehabilitation, and lifestyle changes can help manage symptoms and improve quality of life.


Get a Free Sample PDF Report to know more about Emphysema Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/emphysema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Emphysema Drugs Under Different Phases of Clinical Development Include:
• Kamada AAT for inhalation: Kamada, Ltd.
• RAR Gamma: Hoffmann-La Roche
• BLVR System: Aeris Therapeutics
• Alpha-1 MP: Grifols Therapeutics
• SAR447537: Sanofi
• ProchymalTM: Mesoblast, Inc.

Emphysema Route of Administration
Emphysema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Emphysema Molecule Type
Emphysema Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Emphysema Pipeline Therapeutics Assessment
• Emphysema Assessment by Product Type
• Emphysema By Stage and Product Type
• Emphysema Assessment by Route of Administration
• Emphysema By Stage and Route of Administration
• Emphysema Assessment by Molecule Type
• Emphysema by Stage and Molecule Type

DelveInsight's Emphysema Report covers around 12+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Emphysema product details are provided in the report. Download the Emphysema pipeline report to learn more about the emerging Emphysema therapies
https://www.delveinsight.com/sample-request/emphysema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Emphysema Therapeutics Market include:
Key companies developing therapies for Emphysema are - AstraZeneca, GlaxoSmithKline, Pfizer, Teva Pharmaceuticals, Novartis, Viatris, Orion Corporation, Boehringer IngelheimAstraZeneca, Teva Pharmaceuticals, xPfizer, Boehringer Ingelheim, and others.

Emphysema Pipeline Analysis:
The Emphysema pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Emphysema with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Emphysema Treatment.
• Emphysema key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Emphysema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Emphysema market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Emphysema drugs and therapies
https://www.delveinsight.com/sample-request/emphysema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emphysema Pipeline Market Drivers
• Rising prevalence of COPD and emphysema, fueled by aging populations and smoking rates-over 16 million US adults have COPD, Advances in therapeutic tech, including inhaled biologics, endobronchial valves, and minimally invasive lung volume reduction procedures, Increased healthcare spending and government initiatives supporting respiratory disease diagnosis and treatment, are some of the important factors that are fueling the Emphysema Market.

Emphysema Pipeline Market Barriers
• However, High cost of advanced diagnostics and treatments, including surgical procedures and biologics, limiting access globally, Limited specialized care, with shortages of trained respiratory professionals in many regions, Side effects from existing therapies, like corticosteroids and bronchodilators, which reduce patient adherence, and other factors are creating obstacles in the Emphysema Market growth.

Scope of Emphysema Pipeline Drug Insight
• Coverage: Global
• Key Emphysema Companies: Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi, Mesoblast, Inc., and others
• Key Emphysema Therapies: Kamada AAT for inhalation, RAR Gamma, BLVR System, Alpha-1 MP, SAR447537, ProchymalTM, and others
• Emphysema Therapeutic Assessment: Emphysema current marketed and Emphysema emerging therapies
• Emphysema Market Dynamics: Emphysema market drivers and Emphysema market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.